O	0	9	Treatment	Treatment	NN	B-NP
O	10	12	of	of	IN	B-PP
O	13	25	transplanted	transplant	VBN	B-NP
B-Cancer	26	30	CT26	CT26	NN	I-NP
I-Cancer	31	37	tumour	tumour	NN	I-NP
O	38	42	with	with	IN	B-PP
B-Cell	43	52	dendritic	dendritic	JJ	B-NP
I-Cell	53	57	cell	cell	NN	I-NP
O	58	65	vaccine	vaccine	NN	I-NP
O	66	68	in	in	IN	B-PP
O	69	80	combination	combination	NN	B-NP
O	81	85	with	with	IN	B-PP
O	86	94	blockade	blockade	NN	B-NP
O	95	97	of	of	IN	B-PP
O	98	106	vascular	vascular	JJ	B-NP
O	107	118	endothelial	endothelial	JJ	I-NP
O	119	125	growth	growth	NN	I-NP
O	126	132	factor	factor	NN	I-NP
O	133	141	receptor	receptor	NN	I-NP
O	142	143	2	2	CD	B-NP
O	144	147	and	and	CC	I-NP
O	148	152	CTLA	CTLA	NN	I-NP
O	152	153	-	-	:	O
O	153	154	4	4	CD	B-NP
O	154	155	.	.	.	O

O	156	158	We	We	PRP	B-NP
O	159	171	investigated	investigate	VBD	B-VP
O	172	175	the	the	DT	B-NP
O	176	180	anti	anti	JJ	I-NP
B-Cancer	181	185	CT26	CT26	NN	I-NP
I-Cancer	186	192	tumour	tumour	NN	I-NP
O	193	199	effect	effect	NN	I-NP
O	200	202	of	of	IN	B-PP
B-Cell	203	212	dendritic	dendritic	JJ	B-NP
I-Cell	213	217	cell	cell	NN	I-NP
O	218	223	based	base	VBN	B-VP
O	224	235	vaccination	vaccination	NN	B-NP
O	236	240	with	with	IN	B-PP
O	241	244	the	the	DT	B-NP
O	245	249	MuLV	MuLV	NN	I-NP
O	250	254	gp70	gp70	NN	I-NP
B-Cellular_component	255	263	envelope	envelope	NN	I-NP
O	264	271	protein	protein	NN	I-NP
O	271	272	-	-	HYPH	B-NP
O	272	279	derived	derive	VBN	I-NP
O	280	288	peptides	peptide	NNS	I-NP
O	289	292	AH1	AH1	NN	I-NP
O	293	296	and	and	CC	I-NP
O	297	301	p320	p320	NN	I-NP
O	301	302	-	-	SYM	B-NP
O	302	305	333	333	CD	B-NP
O	305	306	.	.	.	O

O	307	318	Vaccination	Vaccination	NN	B-NP
O	319	323	lead	lead	VBP	B-VP
O	324	326	to	to	TO	B-PP
O	327	337	generation	generation	NN	B-NP
O	338	340	of	of	IN	B-PP
O	341	344	AH1	AH1	NN	B-NP
O	345	353	specific	specific	JJ	I-NP
B-Cell	354	363	cytotoxic	cytotoxic	JJ	I-NP
I-Cell	364	375	lymphocytes	lymphocyte	NNS	I-NP
O	376	377	(	(	(	O
B-Cell	377	380	CTL	CTL	NN	B-NP
O	380	381	)	)	)	O
O	382	385	and	and	CC	O
O	386	390	some	some	DT	B-NP
O	391	399	decrease	decrease	NN	I-NP
O	400	402	in	in	IN	B-PP
B-Cancer	403	409	tumour	tumour	NN	B-NP
O	410	416	growth	growth	NN	I-NP
O	417	419	of	of	IN	B-PP
O	420	434	simultaneously	simultaneously	RB	B-NP
O	435	445	inoculated	inoculate	VBN	I-NP
B-Cell	446	450	CT26	CT26	NN	I-NP
I-Cell	451	456	cells	cell	NNS	I-NP
O	456	457	.	.	.	O

O	458	463	After	After	IN	B-PP
O	464	475	combination	combination	NN	B-NP
O	476	480	with	with	IN	B-PP
O	481	483	an	an	DT	B-NP
O	484	492	antibody	antibody	NN	I-NP
O	493	500	against	against	IN	B-PP
O	501	505	VEGF	VEGF	NN	B-NP
O	506	514	receptor	receptor	NN	I-NP
O	515	516	2	2	CD	I-NP
O	517	518	(	(	(	O
O	518	523	DC101	DC101	NN	B-NP
O	523	524	)	)	)	O
O	524	525	,	,	,	O
O	526	527	a	a	DT	B-NP
O	528	539	significant	significant	JJ	I-NP
O	540	548	increase	increase	NN	I-NP
O	549	551	in	in	IN	B-PP
O	552	560	survival	survival	NN	B-NP
O	561	563	of	of	IN	B-PP
O	564	567	the	the	DT	B-NP
B-Cell	568	574	tumour	tumour	NN	I-NP
I-Cell	575	579	cell	cell	NN	I-NP
O	580	590	recipients	recipient	NNS	I-NP
O	591	594	was	be	VBD	B-VP
O	595	603	observed	observe	VBN	I-VP
O	603	604	.	.	.	O

O	605	609	Also	Also	RB	B-ADVP
O	609	610	,	,	,	O
O	611	622	monotherapy	monotherapy	NN	B-NP
O	623	627	with	with	IN	B-PP
O	628	630	an	an	DT	B-NP
O	631	639	antibody	antibody	NN	I-NP
O	640	647	against	against	IN	B-PP
O	648	652	CTLA	CTLA	NN	B-NP
O	652	653	-	-	HYPH	B-NP
O	653	654	4	4	CD	I-NP
O	655	656	(	(	(	O
O	656	660	9H10	9H10	NN	B-NP
O	660	661	)	)	)	O
O	661	662	,	,	,	O
O	663	666	led	lead	VBD	B-VP
O	667	669	to	to	TO	B-PP
O	670	683	approximately	approximately	RB	B-NP
O	684	687	100	100	CD	I-NP
O	687	688	%	%	NN	I-NP
O	689	697	survival	survival	NN	I-NP
O	698	700	of	of	IN	B-PP
B-Cell	701	707	tumour	tumour	NN	B-NP
I-Cell	708	712	cell	cell	NN	I-NP
O	713	723	recipients	recipient	NNS	I-NP
O	723	724	.	.	.	O

O	725	732	However	However	RB	B-ADVP
O	732	733	,	,	,	O
O	734	743	effective	effective	JJ	B-NP
O	744	753	treatment	treatment	NN	I-NP
O	754	756	of	of	IN	B-PP
O	757	761	mice	mouse	NNS	B-NP
O	762	766	with	with	IN	B-PP
O	767	774	already	already	RB	B-NP
O	775	786	established	establish	VBN	I-NP
B-Cancer	787	794	tumours	tumour	NNS	I-NP
O	795	798	was	be	VBD	B-VP
O	799	803	only	only	RB	I-VP
O	804	812	obtained	obtain	VBN	I-VP
O	813	818	after	after	IN	B-PP
O	819	830	combination	combination	NN	B-NP
O	831	833	of	of	IN	B-PP
O	834	845	vaccination	vaccination	NN	B-NP
O	845	846	,	,	,	I-NP
O	847	852	DC101	DC101	NN	I-NP
O	853	856	and	and	CC	I-NP
O	857	861	9H10	9H10	NN	I-NP
O	862	871	treatment	treatment	NN	I-NP
O	872	874	in	in	IN	B-PP
O	875	880	which	which	WDT	B-NP
O	881	888	setting	set	VBG	B-VP
O	889	891	80	80	CD	B-NP
O	891	892	%	%	NN	I-NP
O	893	895	of	of	IN	B-PP
O	896	899	the	the	DT	B-NP
O	900	904	mice	mouse	NNS	I-NP
O	905	913	rejected	reject	VBD	B-VP
O	914	919	their	their	PRP$	B-NP
B-Cancer	920	927	tumours	tumour	NNS	I-NP
O	927	928	.	.	.	O

